COVID-19 Research Paper Volume 13, Issue 12 pp 15770—15784
In silico analysis identifies neuropilin-1 as a potential therapeutic target for SARS-Cov-2 infected lung cancer patients
Figure 3. Survival analysis of cancer patients with differential gene expression level. (A–D) Survival curve of SARC (n=259), CESC (n=304), TGCT (n=134), LUSC (n=501) and LUAD (n=513) patients with differential level of NRP1 expression. (E) Survival curve of LUSC and LUAD patients with differential level of TMPRSS2 expression. Analysis was done with Kaplan-Meier Plotter.